Celcuity Reports the P-III (VIKTORIA-1) Trial Data on Gedatolisib Combination for HR+/HER2- PIK3CA Mutant Advanced Breast Cancer

Why It Matters

The data suggest gedatolisib could become a new standard for patients who have exhausted CDK4/6 inhibitors, potentially reshaping the therapeutic algorithm for HR+/HER2‑negative breast cancer.

Key Takeaways

• Triplet regimen doubled progression‑free survival vs standard of care
• Doublet showed similar PFS improvement with higher duration of response
• Early overall survival trends favor gedatolisib combos
• Celcuity to file supplemental NDA; FDA review due July 2026

Pulse Analysis

The PI3K‑α pathway remains a critical driver of resistance in hormone‑receptor‑positive, HER2‑negative breast cancer, especially after progression on CDK4/6 inhibitors and aromatase inhibitors. Gedatolisib, a pan‑PI3K/mTOR inhibitor, targets multiple isoforms, offering a broader blockade than the selective PI3K‑α inhibitor alpelisib. By pairing gedatolisib with fulvestrant—and optionally adding palbociclib—Celcuity aims to restore endocrine sensitivity while simultaneously curbing downstream signaling that fuels tumor growth.

In the VIKTORIA‑1 trial, the triplet combination more than doubled median progression‑free survival to 11.1 months and nearly doubled the objective response rate to 48.9% compared with the alpelisib‑fulvestrant control. Even the doublet achieved an 11.3‑month mPFS, indicating that gedatolisib’s efficacy is not solely dependent on the CDK4/6 inhibitor backbone. Median duration of response extended to 15.7 months for the triplet and 24.2 months for the doublet, suggesting durable disease control. Early overall‑survival trends, though immature, hint at a potential survival advantage that could differentiate gedatolisib from existing options.

Regulatory momentum is building as Celcuity prepares a supplemental NDA for the PIK3CA‑mutant indication, while a separate NDA for wild‑type disease is under FDA review with a PDUFA date of July 17, 2026. If approved, gedatolisib would enter a market dominated by alpelisib and could capture a sizable share of the $5 billion global HR+/HER2‑negative breast cancer therapy segment. Payers will likely evaluate the cost‑effectiveness of the triplet versus sequential use of CDK4/6 inhibitors and PI3K agents, but the pronounced efficacy gains may justify premium pricing and reshape treatment sequencing strategies.